We can’t show the full text here under this license.
Abstract
The least-squares mean change in body weight is -17.8% for GZR18 administered weekly compared to 0.7% for placebo.
- GZR18 is a glucagon-like peptide-1 receptor agonist being tested for overweight and obesity.
- Sixty participants were enrolled in a randomized, placebo-controlled trial, with 46 completing it.
- In Part A, GZR18 resulted in a -9.36% weight change versus -6.68% for placebo.
- In Part B, GZR18 demonstrated weight changes of -17.8% for weekly dosing and -12.8% for bi-weekly dosing, compared to 0.7% for placebo.
- GZR18 also improves other weight-related and metabolic measures.
- The treatment is generally safe with mild-to-moderate gastrointestinal side effects reported.
Simplified